Article
Amgen Announces Data From Study Comparing Aimovig to Topiramate
Author(s):
Individuals taking erenumab had a 55.4% reduction from baseline in their monthly migraine days, results from HER-MES show.
Amgen has announced new data from the HER-MES study, which is the first and only head-to-head study of erenumab-aooe (Aimovig), a calcitonin gene-related peptide inhibitor, against topiramate for individuals with chronic and episodic migraines.
"We're extremely encouraged by these new results, which demonstrate lower discontinuation rates, due to adverse events and superior efficacy versus topiramate in migraine prevention and strengthen our confidence that Aimovig has significant potential to help many more patients living with migraine," Rob Lenz, MD, PhD, senior vice president of Global Development at Amgen, said in a statement.
In the phase 4 study, the findings show that individuals in the erenumab treatment arm experienced a significantly lower discontinuation rate, because of adverse events (AEs) of 10.6% compared with those taking topiramate at 38.9%.
Individuals taking erenumab had a 55.4% reduction from baseline in their monthly migraine days compared with those taking topiramate at 31.2%.
In the topiramate group, the most frequent AEs that led to discontinuation were disturbance in attention, fatigue, nausea, and paraesthesia.
In the erenumab group, the AEs leading to discontinuation were disturbance in attention, dizziness, fatigue, and nausea.
“The positive outcomes strengthen the efficacy and safety profile of erenumab as a migraine prevention treatment for patients with migraine,” Uwe Reuter, MD, PhD, trial investigator and managing medical director at Charité Universitätsmedizin in Berlin, said in the statement.
The results were published in Cephalalgia.
Reference
First and only randomized, double-blind, head-to-head study Comparing aimovig (erenumab-aooe), an anti-CGRP pathway therapy, to topiramate published in cephalalgia. PRNewswire. November 8, 2021. Accessed November 9, 2021.
